CTRI/2023/02/050070招募中4 期
A PHASE IV, RANDOMIZED, MULTICENTER, OPEN-LABEL, CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB (PHESGO) IN INDIAN PATIENTS WITH HER2-POSITIVE BREAST CANCER
试验速览
- 阶段
- 4 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Signed Informed Consent Form
- •Women of age =18 years at time of signing Informed Consent Form
- •HER2+ breast cancer status confirmed by local laboratory before study enrollment
- •Hormone receptor status of the primary tumor determined by local assessment
排除标准
- •Treatment with investigational therapy within 4 weeks of enrollment
- •Serious cardiac illness or medical conditions
- •History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias
- •Inadequate bone marrow function
研究者
相似试验
进行中（未招募）
1 期
A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, version 2.0 dated 13-Feb-05, andRevised Protocol 02 version 6.0, incorporating Amendment 03 and 04 dated 27-Oct-05 - THE REAL STUDY - RESEARCH INTO ATAZANAVIR IN LIPODYSTROPHYHIV-infected individuals with lipodystrophyEUCTR2004-002740-10-GBBristol-Myers Squibb International Corporation300
进行中（未招募）
不适用
A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, version 2.0 dated 13-Feb-05Revised Protocol 03, version v8.0, incorporating Protocol Amendments 03, 04 and 05 - THE REAL STUDY - RESEARCH INTO ATAZANAVIR IN LIPODYSTROPHYHIV-infected individuals with lipodystrophyEUCTR2004-002740-10-DEBristol-Myers Squibb International Corporation300
进行中（未招募）
不适用
A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, version 2.0 dated 13-Feb-05Revised protocol 02 version 6.0, incorporating Amendment 03 and 04 dated 27-Oct-05. - THE REAL STUDY - RESEARCH INTO ATAZANAVIR IN LIPODYSTROPHYHIV-infected individuals with lipodystrophyEUCTR2004-002740-10-ESBristol-Myers Squibb International Corporation300
招募中
不适用
STUDY OF MANAGEMENT OF PASIREOTIDE-INDUCED HYPERGLYCEMIA IN ADULT PATIENTS WITH CUSHING´S DISEASE OR ACROMEGALY-E240 Pituitary-dependent Cushing disease-E220 Acromegaly and pituitary gigantismAcromegaly and pituitary gigantismPituitary-dependent Cushing diseaseE220E240PER-018-15OVARTIS BIOSCIENSES PERU S.A.,11
进行中（未招募）
1 期
To assess & compare the impact on disease control & patient & practitioner experience between the 6-monthly study drug & available 3-monthly injections. Comparison of the proportions of patients medically castrated & their PSA levels at 6 and 12 months between the 6-monthly study drug & 3-monthly injections. Review of patient satisfaction & preference for the 6-monthly study drug compared to 3-monthly injections & explore the effects of the 6-monthly study drug on the patients’ Quality of Life.locally advanced and metastatic prostrate cancerEUCTR2011-004213-16-GBIpsen Ltd21